Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Kearn, M. Greenberg, R. Dicamelli, Kristin Kurzawa, C. Hillard (1999)
Relationships Between Ligand Affinities for the Cerebellar Cannabinoid Receptor CB1 and the Induction of GDP/GTP ExchangeJournal of Neurochemistry, 72
J. LeLorier, Genevieve Gregoire, Abdeltif Benhaddad, Julie Lapierre, François Derderian (1997)
Discrepancies between meta-analyses and subsequent large randomized, controlled trials.The New England journal of medicine, 337 8
M. Boyce, L. Irwin, R. Barker (2005)
Demographic meta-analysis: synthesizing vital rates for spotted owlsJournal of Applied Ecology, 42
S. Paugh, M. Cassidy, Hengjun He, S. Milstien, L. Sim‐Selley, S. Spiegel, D. Selley (2006)
Sphingosine and Its Analog, the Immunosuppressant 2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, Interact with the CB1 Cannabinoid ReceptorMolecular Pharmacology, 70
H. Andersson, A. D'Antona, D. Kendall, G. Heijne, C. Chin (2003)
Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail.Molecular pharmacology, 64 3
M. Müllner (2001)
Medicinal use of cannabisBMJ : British Medical Journal, 322
J. Sullivan (2002)
Cannabinoid receptorsCurrent Biology, 12
Howlett Howlett (2002)
The cannabinoid receptorsProstaglandins Other Lipid Mediat, 68–69
Susan Huang, T. Bisogno, M. Trevisani, A. Al-Hayani, L. Petrocellis, F. Fezza, M. Tognetto, Timothy Petros, Jocelyn Krey, Constance Chu, Jeffrey Miller, S. Davies, P. Geppetti, J. Walker, V. Marzo (2002)
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptorsProceedings of the National Academy of Sciences of the United States of America, 99
T. Sheskin, L. Hanuš, J. Slager, Zvi Vogel, Raphael Mechoulam (1997)
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.Journal of medicinal chemistry, 40 5
H. Schiöth, T. Haitina, Maria Ling, Aneta Ringholm, R. Fredriksson, J. Cerdá-Reverter, J. Kloviņš (2005)
Evolutionary conservation of the structural, pharmacological, and genomic characteristics of the melanocortin receptor subtypesPeptides, 26
Man-Hee Rhee, Zvi Vogel, Jacob Barg, M. Bayewitch, R. Levy, L. Hanuš, and Breuer, Raphael Mechoulam (1997)
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.Journal of medicinal chemistry, 40 20
H. Isbell, C. Gorodetzsky, D. Jasinski, U. Claussen, F. Spulak, F. Korte (1967)
Effects of (--)delta-9-trans-tetrahydrocannabinol in man.Psychopharmacologia, 11 2
M. Herkenham, A. Lynn, Little, J. Mr, L. Melvin, deCosta Br, K. Rice (1990)
Cannabinoid receptor localization in brain.Proceedings of the National Academy of Sciences of the United States of America, 87 5
S. Eggan, D. Lewis (2006)
Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis.Cerebral cortex, 17 1
J. Haller, F. Mátyás, K. Soproni, B. Varga, B. Barsy, B. Németh, É. Mikics, T. Freund, N. Hájos (2007)
Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmissionThe European Journal of Neuroscience, 25
M. Astolfi, R. Patacchini, M. Maggi, S. Manzini (1997)
Improved discriminatory properties between human and murine tachykinin NK1 receptors of MEN 10930: a new potent and competitive antagonistNeuropeptides, 31
B. Thomas, A. Gilliam, D. Burch, M. Roche, H. Seltzman (1998)
Comparative receptor binding analyses of cannabinoid agonists and antagonists.The Journal of pharmacology and experimental therapeutics, 285 1
E. Carlini, A. Hamaoui, D. Bieniek, F. Korte (1970)
Effects of (--) delta-9-trans-tetrahydrocannabinol and a synthetic derivative on maze performance of rats.Pharmacology, 4 6
R. Browne, A. Weissman (1981)
Discriminative Stimulus Properties of Δ9‐Tetrahydrocannabinol: Mechanistic StudiesThe Journal of Clinical Pharmacology, 21
J. Gong, E. Onaivi, H. Ishiguro, Qing-Rong Liu, P. Tagliaferro, A. Brusco, G. Uhl (2006)
Cannabinoid CB2 receptors: Immunohistochemical localization in rat brainBrain Research, 1071
M. Steffens, C. Engler, J. Zentner, T. Feuerstein (2004)
Cannabinoid CB1 receptor‐mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortexBritish Journal of Pharmacology, 141
H. Isbell, C. Gorodetzsky, D. Jasinski, U. Claussen, F. Spulak, F. Korte (2004)
Effects of (−)Δ9-trans-tetrahydrocannabinol in manPsychopharmacologia, 11
Identification functional characterization of brainstem cannabinoid CB2 receptors.
F. Petitet, M. Donlan, A. Michel (2006)
GPR55 as a New Cannabinoid Receptor: Still a Long Way to Prove ItChemical Biology & Drug Design, 67
Baslingappa Hungund, B. Basavarajappa (2000)
Distinct differences in the cannabinoid receptor binding in the brain of C57BL/6 and DBA/2 mice, selected for their differences in voluntary ethanol consumptionJournal of Neuroscience Research, 60
C. Felder, K. Joyce, E. Briley, J. Mansouri, K. Mackie, O. Blond, Y. Lai, A. Ma, R. Mitchell (1995)
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.Molecular pharmacology, 48 3
F. Petitet, Laurent Marin, A. Doble (1996)
Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716ANeuroReport, 7
J. Sese, S. Morishita (2001)
Rank Aggregation Method for Biological DatabasesGenome Informatics, 12
A. Ohlsson, J. Lindgren, A. Wahlén, S. Agurell, L. Hollister, H. Gillespie (1980)
Plasma delta‐9‐tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smokingClinical Pharmacology & Therapeutics, 28
D. Demuth, A. Molleman (2006)
Cannabinoid signalling.Life sciences, 78 6
R. Pertwee (2005)
Pharmacological actions of cannabinoids.Handbook of experimental pharmacology, 168
J. McPartland, I. Matias, V. Marzo, M. Glass (2006)
Evolutionary origins of the endocannabinoid system.Gene, 370
Reed Reed, Lynn Lynn, Meade Meade (2002)
Use of coefficient of variation in assessing variability of quantitative assaysClin Diagn Lab Immunol, 9
M. Glass, R. Faull, M. Dragunow (1997)
Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brainNeuroscience, 77
Bingham (2007)
Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomersBr J Pharmacol
M. Egertová, M. Elphick (2000)
Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C‐terminal tail of CB1Journal of Comparative Neurology, 422
C. Breivogel, L. Sim, S. Childers (1997)
Regional differences in cannabinoid receptor/G-protein coupling in rat brain.The Journal of pharmacology and experimental therapeutics, 282 3
C. Felder, J. Veluz, H. Williams, E. Briley, L. Matsuda (1992)
Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones.Molecular pharmacology, 42 5
D. Demuth, A. Molleman (2006)
Cannabinoid signalling (review)Life Sciences
Juha Savinainen, S. Saario, R. Niemi, T. Järvinen, J. Laitinen (2003)
An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptorsBritish Journal of Pharmacology, 140
D. Baker, G. Pryce, Wayne Davies, C. Hiley (2006)
In silico patent searching reveals a new cannabinoid receptor.Trends in pharmacological sciences, 27 1
D. Houston, A. Howlett (1998)
Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists.Cellular signalling, 10 9
F. Fonseca, M. Gorriti, J. Fernández-Ruiz, Tomás Palomo, J. Ramos (1994)
Downregulation of rat brain cannabinoid binding sites after chronic Δ 9-tetrahydrocannabinol treatmentPharmacology Biochemistry and Behavior, 47
Supplementary Information accompanies the paper on
A. Hoffman, Alice Macgill, D. Smith, M. Oz, C. Lupica (2005)
Species and strain differences in the expression of a novel glutamate‐modulating cannabinoid receptor in the rodent hippocampusEuropean Journal of Neuroscience, 22
J. Arnold, A. Topple, P. Mallet, G. Hunt, I. McGregor (2001)
The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strainBrain Research, 921
J. Romero, J. Fernández-Ruiz, G. Vela, M. Ruiz‐Gayo, J. Fuentes, J. Ramos (1998)
Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice.Drug and alcohol dependence, 50 3
John Overington, B. Al-Lazikani, A. Hopkins (2006)
How many drug targets are there?Nature Reviews Drug Discovery, 5
F. Mauler, J. Mittendorf, E. Horváth, J. Vry (2002)
Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties.The Journal of pharmacology and experimental therapeutics, 302 1
Neuroreport
J. Wiley, J. Lowe, R. Balster, B. Martin (1995)
Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.The Journal of pharmacology and experimental therapeutics, 275 1
Rodriguez de Fonseca Rodriguez de Fonseca, Gorriti Gorriti, Fernandez‐Ruiz Fernandez‐Ruiz, Palomo Palomo, Ramos Ramos (1994)
Downregulation of rat brain cannabinoid binding sites after chronic delta 9‐tetrahydrocannabinol treatmentPharmacol Biochem Behav, 47
C. Breivogel, G. Griffin, V. Marzo, B. Martin (2001)
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.Molecular pharmacology, 60 1
(1995)
Doctorate Dissertation, Department of Pharmacology and Clinical Pharmacology
B. Thomas, M. Francisco, H. Seltzman, James Thomas, S. Fix, Anne-Kathrin Schulz, A. Gilliam, R. Pertwee, L. Stevenson (2005)
Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities.Bioorganic & medicinal chemistry, 13 18
G. Reed, F. Lynn, B. Meade (2002)
Use of Coefficient of Variation in Assessing Variability of Quantitative AssaysClinical and Vaccine Immunology, 9
W. Cochran (1954)
The combination of estimates from different experiments.Biometrics, 10
G. Glass, B. Mcgaw, M. Smith (1981)
Meta-analysis in social research
R. Pertwee, A. Thomas, L. Stevenson, Y. Maor, R. Mechoulam (2005)
Evidence that (−)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferensNeuropharmacology, 48
L. Martini, M. Waldhoer, Margareta Pusch, V. Kharazia, Jamie Fong, Josephine Lee, C. Freissmuth, J. Whistler (2007)
Ligand‐induced down‐regulation of the cannabinoid 1 receptor is mediated by the G‐protein‐coupled receptor‐associated sorting protein GASP1The FASEB Journal, 21
E. Russo, Andrea Burnett, B. Hall, K. Parker (2005)
Agonistic Properties of Cannabidiol at 5-HT1a ReceptorsNeurochemical Research, 30
I. Díaz-Laviada, Lidia Ruiz-Llorente (2005)
Signal transduction activated by cannabinoid receptors.Mini reviews in medicinal chemistry, 5 7
T. Järbe, J. Johansson, B. Henriksson (1976)
Characteristics of tetrahydrocannabinol (THC)-produced discrimination in ratsPsychopharmacology, 48
T. Harkany, M. Dobszay, F. Cayetanot, W. Härtig, T. Siegemund, F. Aujard, K. Mackie (2005)
Redistribution of CB1 cannabinoid receptors during evolution of cholinergic basal forebrain territories and their cortical projection areas: A comparison between the gray mouse lemur (Microcebus murinus, primates) and ratNeuroscience, 135
A. Szallasi (1994)
The vanilloid (capsaicin) receptor: receptor types and species differences.General pharmacology, 25 2
R. Browne, A. Weissman (1981)
Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies.Journal of clinical pharmacology, 21 S1
B. Bingham, Philip Jones, A. Uveges, S. Kotnis, P. Lu, V. Smith, Shaiu-Ching Sun, L. Resnick, M. Chlenov, Y. He, B. Strassle, T. Cummons, M. Piesla, J. Harrison, G. Whiteside, J. Kennedy (2007)
Species‐specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomersBritish Journal of Pharmacology, 151
A meta‐analysis, unlike a literature review, synthesizes previous studies into new results. Pooled data from 211 studies measured ligand binding affinities at human (Hs) or rat (Rn) cannabinoid receptors CB1 and CB2. Cochrane methods were modified for this non‐clinical analysis. Meta‐regression detected data heterogeneity arising from methodological factors: use of sectioned tissues, lack of PMSF and choice of radioligand. Native brain tissues exhibited greater affinity (lower nM) than transfected cells, but the trend fell short of significance, as did the trend between centrifugation and filtration methods. Correcting for heterogeneity, mean Ki values for Δ9‐tetrahydrocannabinol differed significantly between HsCB1 and RnCB1 (25.1 and 42.6 nM, respectively) but not between HsCB1 and HsCB2 (25.1 and 35.2). Mean Kd values for HsCB1, RnCB1 and HsCB2 of CP55,940 (2.5, 0.98, 0.92) and WIN55,212‐2 (16.7, 2.4, 3.7) differed between HsCB1 and RnCB1 and between HsCB1 and HsCB2. SR141716A differed between HsCB1 and RnCB1 (2.9 and 1.0 nM). Anandamide at HsCB1, RnCB1 and HsCB2 (239.2, 87.7, 439.5) fell short of statistical differences due to heterogeneity. We consider these Kd and Ki values to be the most valid estimates in the literature. Sensitivity analyses did not support the numerical validity of cannabidiol, cannabinol, 2‐arachidonoyl glycerol and all ligands at RnCB2. Aggregate rank order analysis of CB1 distribution in the brain (pooled from 119 autoradiographic, immunohistochemical and in situ hybridization studies) showed denser HsCB1 expression in cognitive regions (cerebral cortex) compared to RnCB1, which was relatively richer in movement‐associated areas (cerebellum, caudate‐putamen). Implications of interspecies differences are discussed. British Journal of Pharmacology (2007) 152, 583–593; doi:10.1038/sj.bjp.0707399; published online 16 July 2007
British Journal of Pharmacology – Wiley
Published: Nov 1, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.